Open AccessReview of the Omnipod® 5 Automated Glucose Control System Powered by Horizon™ for the treatment of Type 1 diabetes
Author(s) -
Erin Cobry,
Cari Berget,
Laurel H. Messer,
Gregory P. Forlenza
Publication year - 2020
Publication title -
therapeutic delivery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.619
H-Index - 46
eISSN - 2041-6008
pISSN - 2041-5990
DOI - 10.4155/tde-2020-0055
Subject(s) - diabetes mellitus , type 1 diabetes , medicine , diabetes management , type 2 diabetes , intensive care medicine , control (management) , clinical trial , insulin , horizon , closed loop , computer science , endocrinology , engineering , mathematics , artificial intelligence , control engineering , geometry
Type 1 diabetes (T1D) is a medical condition that requires constant management, including monitoring of blood glucose levels and administration of insulin. Advancements in diabetes technology have offered methods to reduce the burden on people with T1D. Several hybrid closed-loop systems are commercially available or in clinical trials, each with unique features to improve care for patients with T1D. This article reviews the Omnipod ® 5 Automated Glucose Control System Powered by Horizon™ and the safety and efficacy data to support its use in the management of T1D.